A novel approach to identify candidate prognostic factors for hepatitis C treatment response integrating clinical and viral genetic data.

ABSTRACT: The combined therapy of pegylated interferon (IFN) plus ribavirin (RBV) has been for a long time the standard treatment for patients infected with hepatitis C virus (HCV). In the case of genotype 1, only 38%-48% of patients have a positive response to the combined treatment. In previous studies, viral genetic information has been occasionally included as a predictor. Here, we consider viral genetic variation in addition to 11 clinical and 19 viral populations and evolutionary parameters to identify candidate baseline prognostic factors that could be involved in the treatment outcome. We obtained potential prognostic models for HCV subtypes la and lb in combination as well as separately. We also found that viral genetic information is relevant for the combined treatment assessment of patien

SUBMITTER: Amadoz A 

PROVIDER: S-EPMC4344356 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature